M De Laurentiis
Overview
Explore the profile of M De Laurentiis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Conte P, Ascierto P, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al.
ESMO Open
. 2022 Feb;
7(2):100404.
PMID: 35219244
Background: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. Antineoplastic drugs are the primary cause...
12.
Slamon D, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al.
Ann Oncol
. 2021 Aug;
32(10):1307.
PMID: 34412950
No abstract available.
13.
Slamon D, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al.
Ann Oncol
. 2021 Jun;
32(8):1015-1024.
PMID: 34102253
Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC)....
14.
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, et al.
ESMO Open
. 2021 Apr;
6(2):100097.
PMID: 33926709
No abstract available.
15.
Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, et al.
ESMO Open
. 2021 Apr;
6(2):100099.
PMID: 33819752
Background: The current standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive (+) metastatic breast cancer is the combination of pertuzumab, trastuzumab and a taxane (P + T ...
16.
De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, et al.
ESMO Open
. 2021 Feb;
6(2):100054.
PMID: 33601296
Background: We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic...
17.
Dent S, Cortes J, Im Y, Dieras V, Harbeck N, Krop I, et al.
Ann Oncol
. 2020 Nov;
32(2):197-207.
PMID: 33186740
Background: The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. Patients And Methods:...
18.
Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, et al.
Int J Cardiol
. 2019 Jun;
292:171-179.
PMID: 31160077
Background: The immunotherapy has revolutionized the world of oncology in the last decades with considerable advantages in terms of overall survival in cancer patients. The association of Pembrolizumab and Trastuzumab...
19.
Adams S, Loi S, Toppmeyer D, Cescon D, De Laurentiis M, Nanda R, et al.
Ann Oncol
. 2018 Nov;
30(3):405-411.
PMID: 30475947
Background: Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are needed. In cohort B of the phase II KEYNOTE-086...
20.
Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, et al.
Cancer Treat Rev
. 2018 Jun;
68:102-110.
PMID: 29940524
Triple negative breast cancer (TNBC) represents the 15-20% of all breast cancers (BC) and is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a single...